Eloxx Pharmaceuticals
Most recent annual filing: 2026-03-15
- Exaluren NMAS Ph2b start3Q 2026Exaluren NMAS Ph2b start, 3Q 2026, material
- Exaluren nmADPKD enrollment done2027Exaluren nmADPKD enrollment done, 2027, routine
- Exaluren NMAS toplinemid-2027Exaluren NMAS topline, mid-2027, thesis-defining
- Exaluren NMAS toplineby mid-2027Exaluren NMAS topline, by mid-2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
ZKN-013
Small Molecule Target: ribosome, COL7A1, LAMB3
Biotech Distilled coverage (2)
- 2026-08-12 UPDATE: Eloxx Pharmaceuticals (ELOX) - The Quarter Where the Money Showed Up and the Trial Didn’t 🔒 Paid
- 2026-06-18 Eloxx Pharmaceuticals (ELOX) — Scientific Deep Dive for Exaluren and the Ribosomal Readthrough Pipeline 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.